Federal Court Upholds Use of “Clinical Similarities” to Assess PMPRB Reporting Jurisdiction

In Galderma’s long-running dispute with the PMPRB, the Federal Court (per Fothergill J.) recently upheld the PMPRB’s decision that Galderma’s patent claiming the use of a 0.3% adapalene formulation “pertained” to its DIFFERIN (0.1% adapalene) product. Galderma Canada Inc. v. Canada (Attorney General) – Federal Court (fct-cf.gc.ca) This is the most recent chapter in a […]

Federal Court Upholds Use of “Clinical Similarities” to Assess PMPRB Reporting Jurisdiction Read More »